PBCB Prospective Breast Cancer Biobanking
|
|
|
- Cecil Conley
- 5 years ago
- Views:
Transcription
1 PBCB Prospective Breast Cancer Biobanking Personal monitoring of breast cancer Medicine Biomarkers Patient journey Fatigue Work-life participation Established by Ernst Lien (Bergen) Gunnar Mellgren (Bergen), Håvard Søiland (Stavanger) --- Presented by Marie Austdal, PhD Research Coordinator
2 2 Design Longitudinal, prospective cohort study Newly diagnosed, operable breast cancer patients in Western Norway Total goal: 1200 patients Founded in 2010 (Bergen) 2012 (Stavanger)
3 3 Operable breast cancer patients 11 years follow up Biobank description Diagnosis: blood draw, tissue, questionnaire (Bi-)Yearly study visits: blood draw, questionnaire Endocrine therapy switch or reduction: extra blood draws Recurrence: blood draws, metastasis tissue Urine Blood components Serum, plasma, whole blood (EDTA) PAXgene, CPT Buffy coat, platelets Circulating tumor cells Tissue Fresh frozen (FF) tumor (n~150) Paraffin-embedded tumor FF paracrine adipose tissue (n=32) Metastasis tissue if available In total 32 aliquotes total per visit stored at -80 o C
4 Clinical and phenotypic data Diagnoses, stages and grades Pathology Hormone status Proliferation Treatment Chemotherapy Endocrine therapy Radiation Current follow up status Active patients 312 SUS 780 HUS Relapse (SUS) 3% (SUS) 9 patients Drop-out rate 8% SUS 19% HUS Mainly T 1,2 N 0 M 0 (Stage I-II) at inclusion pt2 Tumor size in situ pt1 Diagnosis ILC DCIS IDC Nodal status pn2 pn1 pn0 DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma 4
5 4 Clinical and phenotypic data Yearly questionnaires At home Self reported health status Quality of life (EORTC) Uncertainty in illness (MUIS) Hospital anxiety and depression (HAD) Dietary changes Functional assessment of cancer therapy (FACT, FACIT) At visit Fatigue (FSS, VAS) Endocrine therapy side effects Medical therapy adherence (MMAS)
6 Clinical and phenotypic data Databank/meta-data LabVantage sample tracking (2018 -> ) Boomerang temperature monitoring Clinical, phenotypic and questionaire data in updated Access-database Image: 4
7 Clinical and phenotypic data External resources in consent General registries National person-, medical birth-, and welfare registries Specific registries The Cancer-, death-, and patient registries, the national prescription database + others Electronic medical records Consent for patient recontact Image: 4
8 5 Research focus The Hormone Laboratory research group (HUS) Gunnar Mellgren Obesity, diabetes, breast cancer and stem cells. Biomarkers of disease development and responsiveness to therapy, tamoxifenn metabolism Forskningsgruppen for Brystkreft (SUS) Håvard Søiland Breast cancer biology, treatment and monitoring during follow-up Circulating tumor cells + DNA, biomarkers in primary tumor, microrna, metabolomics Areas of special interest for industry: Blood-based biomarkers Relapse detection Therapy response Medical doctors, nurses, scientists and technicians with background in medicine, endocrinology, biochemistry, molecular biology, and nutrition.
9 5 Research focus International collaborators: Deirdre Cronin-Fenton «Case-control biobank» Ritu Aneja Padmashree Rida «Biomarkers for therapy response» Mylin Torres Timothy Lash «Fatigue in breast cancer survivors»
10 6 C A S E S T U DY: TA M OX I F E N M E TA B O L I S M Tamoxifen CYP2D6 Active metabolites LC-MS/MS for metabolite measurement (Hormone Laboratory, HUS) Serum concentrations of active tamoxifen metabolites predict survival (Helland, 2017) Prospective observation study of 200 patients in PBCB: Metabolism, side effects, adherence Thomas Helland PhD Candidate Hormone Laboratory Haukeland University Hospital
11 7 How to collaborate? Project outline and material needs to PBCB steering committee If approved: Detailed protocol & material REK approval MTA, co-author agreement Final approval by steering committee More information at Contact Gunnar Mellgren Håvard Søiland
My Personalized Breast Cancer Worksheet
My Personalized Breast Cancer Worksheet KNOW For Early-Stage Breast Cancer. No Questions. Only Results. No two tumors are alike. What are the characteristics of your breast cancer and how will that effect
The Norwegian PSC Research Center Biobank
The Norwegian PSC Research Center Biobank Trine Folseraas Norwegian PSC Research Center, Department of Transplantation Medicine, Division of Surgery, Inflammatory Medicine and Transplantation, Oslo University
Wellness Along the Cancer Journey: Cancer Types Revised October 2015 Chapter 2: Breast Cancer
Wellness Along the Cancer Journey: Cancer Types Revised October 2015 Chapter 2: Breast Cancer Cancer Types Rev. 10.20.15 Page 19 Breast Cancer Group Discussion True False Not Sure 1. Breast cancer is not
Role of Cancer Registries and Data Banking in Quality Control of Breast Cancer Care
4 th International Congress of Breast Role of Cancer Registries and Data Banking in Quality Control of Breast Cancer Care Adri C. Voogd, PhD, epidemiologist Department of Epidemiology, Maastricht University
Contralateral Prophylactic Mastectomy with Immediate Reconstruction: Added Benefits, Added Risks
Contralateral Prophylactic Mastectomy with Immediate Reconstruction: Added Benefits, Added Risks Grant W. Carlson Wadley R. Glenn Professor of Surgery Divisions of Plastic Surgery & Surgical Oncology Emory
UK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
4/13/2010. Silverman, Buchanan Breast, 2003
Tailoring Breast Cancer Treatment: Has Personalized Medicine Arrived? Judith Luce, M.D. San Francisco General Hospital Avon Comprehensive Breast Care Center Outline First, treatment of DCIS Sorting risk
Slide 1. Slide 2. Slide 3 History of Nurse Navigator
Slide 1 The Nurse Navigators role in Early Stage Breast Cancer, and Development of Tailored Treatment Plan Laura Ochoa, RN, ANP-BC, Ph.D. Slide 2 Barnes Jewish Hospital at Washington University Slide 3
Breast Health: An Overview. Breast Cancer Conqueror 2016
Breast Health: An Overview Progress is impossible without change, and those who cannot change their minds cannot change anything. -George Bernard Shaw Types of Breast Cancer 1. Estrogen receptor positive,
Introduction. Wilfred Truin 1 Rudi M. H. Roumen. Vivianne C. G. Tjan-Heijnen 2 Adri C. Voogd
Breast Cancer Res Treat (2017) 164:133 138 DOI 10.1007/s10549-017-4220-x EPIDEMIOLOGY Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients
Breast Cancer Services in Germany
Breast Cancer Services in Germany COUNTRY DELEGATES WORKSHOP Ispra (VA) - 13 and 14 March 2013 Karen Budewig, Federal Ministry of Health, Germany Vanessa Kääb-Sanyal, Mammography-Screening-Program, Germany
BREAST MRI. Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School
BREAST MRI Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School BREAST MRI Any assessment of the breast parenchyma requires the administration
Final Data Report Objective 4. A data report submitted to the National Mango Board Aug 15, 2015
COLLEGE OF AGRICULTURE AND LIFE SCIENCES Department of Nutrition and Food Science Final Data Report 2013-2014 Objective 4 A data report submitted to the National Mango Board Aug 15, 2015 220K Centeq A
Temporal trends in the incidence of molecular subtypes of breast cancer. Jonine D. Figueroa, Ph.D., M.P.H.
Temporal trends in the incidence of molecular subtypes of breast cancer Jonine D. Figueroa, Ph.D., M.P.H. Epidemiology: Health data science Study of the distribution and determinants of health and disease
Optical Intra-operative Assessment of Breast Tumor Margins
Optical Intra-operative Assessment of Breast Tumor Margins Stephanie Kennedy and Torre Bydlon Department of Biomedical Engineering Fitzpatrick Institute of Photonics Duke University 2 Ann Surg Onc 15:1271-1272,
Triple Negative Breast Cancer
Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional
PRECISION MEDICINE FEASIBILITY STUDIES ELECTRONIC HEALTH RECORD TAILORED TREATMENT CANCER
INFECTIONS ALZHEIMER S DISEASE MULTIMORBIDITY PREGNANCY CARDIOVASCULAR DISEASE DIAGNOSTICS PATIENT JOURNEYS REAL WORLD DATA BIOMARKERS PHARMACOGENOMICS BIOBANKS PRAGMATIC TRIALS BIG DATA MEDICAL HISTORY
Basement membrane in lobule.
Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.
HEALTH CARE DISPARITIES. Bhuvana Ramaswamy MD MRCP The Ohio State University Comprehensive Cancer Center
HEALTH CARE DISPARITIES Bhuvana Ramaswamy MD MRCP The Ohio State University Comprehensive Cancer Center Goals Understand the epidemiology of breast cancer Understand the broad management of breast cancer
BREAST MRI. Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School
BREAST MRI Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School BREAST MRI Any assessment of the breast parenchyma requires the administration
Short Term Cancer Risk
in a Cohort of 2312 Women with High Risk Breast Lesions Kubat E 1, Puligandla B 2, Collins L 3, Jiang SF 4, Callahan M 5, Kutner S 6, Habel L 4, Shim V 1 1 Surgery, Kaiser Permanente, Oakland, CA; 2 Pathology,
Ca in situ e ormonoterapia. Discussant : LORENZA MARINO
Ca in situ e ormonoterapia Discussant : LORENZA MARINO Ca in situ e ormonoterapia Quali fattori di rischio? Radioterapia? Ormonoterapia? BCS Recurrence rates (FUP 13-20y) Cuzick, Lancet Oncol.2011; 12(1):
Minimizing Errors in Diagnostic Pathology
Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine-Jacksonville Medical Director, Shands Jacksonville Breast Health Center
Janus Serum Bank. Hilde Langseth MSc, PhD Senior Researcher and head of Janus Serum Bank Cancer Registry of Norway Department of Research
Janus Serum Bank Hilde Langseth MSc, PhD Senior Researcher and head of Janus Serum Bank Cancer Registry of Norway Department of Research Biobank Conference March 13th 2018 Felix konferansesenter, Oslo
Follow-up Issues for Early Stage Breast Cancer: The Role of Surveillance and Long-Term Care
Follow-up Issues for Early Stage Breast Cancer: The Role of Surveillance and Long-Term Care Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of
Patient Guide to Breast Cancer Surgery and Treatment
Patient Guide to Breast Cancer Surgery and Treatment An educational guide prepared by Genomic Health This is your booklet. It is designed to help you through this challenging time. Use it as a guide during
Breast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
Follow-up Care of Breast Cancer Patients
Follow-up Care of Breast Cancer Patients Dr. Simon D. Baxter, MD, FRCPC Medical Oncologist BC Cancer Kelowna Clinical Instructor, Dept of Medicine University of British Columbia 24 November 2018 Disclosures
PATIENT INFORMATION. (Last) (First) (Middle) (Last) (City) (State) (Zip)
PATIENT INFMATION : Address: (Last) (First) (Middle) (Last) (City) (State) (Zip) Home Phone: Cell Phone: Email address: Birth date: : Gender: When is the best time to contact you? May we email you for
Breast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
Contents 1 The Windows of Susceptibility to Breast Cancer 2 The So Called Pre-Neoplastic Lesions and Carcinoma In Situ
Contents 1 The Windows of Susceptibility to Breast Cancer... 1 1.1 Introduction... 1 1.2 Risk Factor and Etiological Agents... 2 1.3 The Concept of the Windows of Susceptibility to Carcinogenesis... 5
Breast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
Breast Cancer Statistics
1 in 8 Breast Cancer Statistics Incidence Mortality Prevalence 2 Breast Cancer Incidence Breast Cancer Mortality Breast Cancer Prevalence ~$100,000 Female Breast Anatomy Breasts consist mainly of fatty
PET/CT in breast cancer staging
PET/CT in breast cancer staging Anni Morsing Consultant, PhD, DMSc Rigshospitalet 1 18F- FDG PET/CT for breastcancer staging Where is the clinical impact? To which women should 18F- FDG PET/CT be offered?
When do you need PET/CT or MRI in early breast cancer?
When do you need PET/CT or MRI in early breast cancer? Elizabeth A. Morris MD FACR Chief, Breast Imaging Service Memorial Sloan-Kettering Cancer Center NY, NY Objectives What is the role of MRI in initial
Intraoperative. Radiotherapy
Intraoperative Radiotherapy ROBERTO ORECCHIA UNIVERSITY of MILAN & EUROPEAN INSTITUTE of ONCOLOGY & CNAO FOUNDATION Breast Cancer Brescia, 30th September 2011 IORT, very selective technique to intensify
Mind and Body in ADHD: somatic comorbidity
Mind and Body in ADHD: somatic comorbidity Jan Haavik K.G. Jebsen Centre for Research on Neuropsychiatric Disorders Department of Biomedicine Haukeland University Hospital University of Bergen, Norway
Disclosure. Objectives 03/19/2019. Current Issues in Management of DCIS Radiation Oncology Considerations
Current Issues in Management of DCIS Radiation Oncology Considerations Fariba Asrari, M.D. Director. Johns Hopkins Breast Center at Green Spring Station Department of Radiation Oncology & Molecular Sciences
Index. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, for early-stage triple-negative breast cancer, 740 742 in older early-stage breast cancer patients, 790 795 anti-her2-directed
Breast Cancer. Common kinds of breast cancer are
Breast Cancer A breast is made up of three main parts: glands, ducts, and connective tissue. The glands produce milk. The ducts are passages that carry milk to the nipple. The connective tissue (which
MammaPrint Improving treatment decisions in breast cancer Support and Involvement of EU
MammaPrint Improving treatment decisions in breast cancer Support and Involvement of EU 1 Bas van der Baan VP Clinical Affairs Irvine, California Amsterdam, The Netherlands 2 Two Crucial Questions in Cancer
Objectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration
Objectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration of endocrine therapy 4. Advances in HER2 directed
Study Of Letrozole Extension. Coordinating Group IBCSG IBCSG BIG 1-07
tudy Of Letrozole Extension Coordinating Group IBCSG IBCSG 35-07 BIG 1-07 A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant
Table S2. Expression of PRMT7 in clinical breast carcinoma samples
Table S2. Expression of PRMT7 in clinical breast carcinoma samples (All data were obtained from cancer microarray database Oncomine.) Analysis type* Analysis Class(number sampels) 1 2 3 4 Correlation (up/down)#
Breast Cancer. American Cancer Society
Breast Cancer American Cancer Society Reviewed February 2017 What we ll be talking about How common is breast cancer? What is breast cancer? What causes it? What are the risk factors? Can breast cancer
2017 San Antonio Breast Cancer Symposium: Local Therapy Highlights
2017 San Antonio Breast Cancer Symposium: Local Therapy Highlights Mylin A. Torres, M.D. Director, Glenn Family Breast Center Associate Professor Department of Radiation Oncology Winship Cancer Institute
Carcinoma mammario: le istologie non frequenti. Valentina Guarneri Università di Padova IOV-IRCCS
Carcinoma mammario: le istologie non frequenti Valentina Guarneri Università di Padova IOV-IRCCS Histological diversity of breast adenocarcinomas Different histological types are defined according to specific
Ines Buccimazza 16 TH UP CONTROVERSIES AND PROBLEMS IN SURGERY SYMPOSIUM
BILATERAL MASTECTOMY IS NOT ROUTINELY JUSTIFIED IN PATIENTS WITH BILATERAL AXILLARY LYMPHADENOPATHY AND ONLY ONE DETECTABLE PRIMARY BREAST CANCER LESION SURGERY SYMPOSIUM Ines Buccimazza Breast Unit Department
Molecular Characterization of Breast Cancer: The Clinical Significance
Molecular Characterization of : The Clinical Significance Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine-Jacksonville
Have you been recently diagnosed with DCIS?
Have you been recently diagnosed with DCIS? Jen D. A busy mother of two and active community volunteer. Jen D. A busy mother of 2 and active community volunteer. *DCIS = Ductal carcinoma in situ AnAn educational
Centre for Research Ethics & Bioethics
Managing incidental findings and research results in genomics Mats Hansson Assigning rights to donors, Wolf et al. Gen Med 2012 Adapted from biobank context: 1. Clarify the criteria for evaluating findings
STAGE CATEGORY DEFINITIONS
CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX Tis Tis (DCIS) Tis (LCIS) Tis (Paget s) T1 T1mi T1a T1b T1c a b c
Breast Cancer in Childhood Cancer Survivors: The Impact of Screening on Morbidity
Breast Cancer in Childhood Cancer Survivors: The Impact of Screening on Morbidity WORKING GROUP: This report will be written within the Cancer Control Working Group with oversight from the Second Malignant
Clinical utility of cancer biomarkers assessed by virtual microscopy
Clinical utility of cancer biomarkers assessed by virtual microscopy Lina Seiz Clinical Research Unit Head: Prof. Dr. Manfred Schmitt Department of Obstetrics and Gynecology Klinikum rechts der Isar Established
2016 CANCER PROGRAM REPORT. Bay Medical Sacred Heart Health System 615 North Bonita Avenue Panama City, FL
2016 CANCER PROGRAM REPORT Bay Medical Sacred Heart Health System 615 North Bonita Avenue Panama City, FL 32401 850.769.1511 www.baymedical.org 2016 Cancer Program Report Bay Medical Sacred Heart provides
Interpretation of Breast Pathology in the Era of Minimally Invasive Procedures
Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine Jacksonville Medical Director, UF Health Breast Center Chief of Pathology
Hormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension?
Hormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension? Ivana Sestak, PhD Centre for Cancer Prevention Wolfson Institute of Preventive Medicine Queen Mary University London
Understanding and Optimizing Treatment of Triple Negative Breast Cancer
Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology Program Leader, Gastrointestinal Oncology Department
Prevention and Screening for Breast Cancer
Cancer Expert Working Group on Cancer Prevention and Screening Prevention and Screening for Breast Cancer Information for women and their families 1 What is breast cancer? The female breast is mainly consisted
Radiation Treatment for Breast. Cancer. Melissa James Radiation Oncologist August 2015
Radiation Treatment for Breast Cancer Melissa James Radiation Oncologist August 2015 OUTLINE External Beam Radiation treatment. (What is Radiation, doctor?) Role of radiation. (Why am I getting radiation,
BREAST CANCER SITE STUDY REPORT By Robert O. Maganini, M.D., F.A.C.S. Breast Surgeon, Alexian Brothers Medical Group
BREAST CANCER SITE STUDY REPORT By Robert O. Maganini, M.D., F.A.C.S. Breast Surgeon, Alexian Brothers Medical Group Breast cancer is the most common cancer diagnosed in women around the world. In the
Breast Cancer. For breast cancer, the mortality risk varies with the stage of the cancer.
CREATED EXCLUSIVELY FOR FINANCIAL PROFESSIONALS Rx FOR SUCCESS Breast Cancer Breast cancer is the most common cancer in women in the United States and second only to lung cancer as a cause of cancer deaths.
IOM Workshop: Achieving Value in Cancer Care: ASCO s Top 5 and Beyond Lowell E. Schnipper, M.D.
IOM Workshop: Achieving Value in Cancer Care: ASCO s Top 5 and Beyond Lowell E. Schnipper, M.D. Expenditures Cancer Care: 2010 Initial dx, continuing care, last phase Costs of Cancer Care: breast, colorectal,
Radiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
SSO-ASTRO Consensus Guidance Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer
SSO-ASTRO Consensus Guidance Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer Dr. Yvonne Tsang St. Paul s Hospital Introductions Breast-conserving
The Cambridge Breast Unit
The Addenbrooke s Hospital Cambridge Cambridge Follow up- Why?- Medical Monitor and treat Acute side effects of treatment Early detection of Local and Regional Recurrences (Curative) Early detection of
Breast Cancer Surgery Options
YOUR VALUES YOUR PREFERENCES YOUR CHOICE Breast Cancer Surgery Options Lumpectomy With Radiation Therapy or Mastectomy Members of Your Health Care Team Breast surgeon A breast surgeon will talk with you
BAYLOR SCOTT & WHITE HEALTH GENETICS QUESTIONNAIRE PATIENT INFORMATION
PATIENT INFORMATION Name: Address: (Last) (First) (Middle) (Street) (City) (State) (Zip) Home Phone: Cell Phone: Email Address: Birth Date: Age: When is the best time to contact you? May we email you for
8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview
Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay
GENETIC TESTING FOR TAMOXIFEN TREATMENT
GENETIC TESTING FOR TAMOXIFEN TREATMENT Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical
UMC- Maastricht. UMC- Groningen Erasmus MC VUMC TOTAL. NKI UMC-Utrecht Leiden UMC. 245,000-Linn, PKAinduced. of ERa at serine 305 and
NKI UMC-Utrecht Leiden UMC UMC- Maastricht UMC- Groningen Erasmus MC VUMC TOTAL 224,000-Linn, PKAinduced high PAK1 levels is 224,000-van Diest, to tamoxifen in ER-positive in 2007 TOTAL 224,000 224,000
Breast Cancer Diagnosis, Treatment and Follow-up
Breast Cancer Diagnosis, Treatment and Follow-up What is breast cancer? Each of the body s organs, including the breast, is made up of many types of cells. Normally, healthy cells grow and divide to produce
Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
Follow-up Care of Breast Cancer Patients
Follow-up Care of Breast Cancer Patients Dr. Simon D. Baxter, MD, FRCPC Medical Oncologist BC Cancer Kelowna Clinical Instructor, Dept of Medicine University of British Columbia 19 April 2018 Disclosures
Screening Mammograms: Questions and Answers
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Screening Mammograms:
Clinical outcomes of patients treated with accelerated partial breast irradiation with high-dose rate brachytherapy: Scripps Clinic experience
Original Article Clinical outcomes of patients treated with accelerated partial breast irradiation with high-dose rate brachytherapy: Scripps Clinic experience Rachel Murray 1, Fantine Giap 2, Ray Lin
It is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
Breast Cancer Treatment
Breast Cancer Treatment Treatment 2 aspects 1. Treatment of the breast itself: Local Treatment 2. Treatment of the whole body = Systemic treatment Local Treatment Surgery +/- Radiation Usually: a. Breast
The Changing Cancer Patient Experience: What do we know and where should we go? Prof. Kerri Clough 22 September 2018
The Changing Cancer Patient Experience: What do we know and where should we go? Prof. Kerri Clough 22 September 2018 Who am I? A public heath professional Professor of cancer epidemiology Director of National
Breast Cancer Task Force of the Greater Miami Valley A collaborative effort of health care professionals and breast cancer survivors in the Greater
Breast Cancer Task Force of the Greater Miami Valley A collaborative effort of health care professionals and breast cancer survivors in the Greater Dayton Area Last Updated Fall 2014 TABLE OF CONTENTS
Breast Cancer Assays of Genetic Expression in Tumor Tissue
Breast Cancer Assays of Genetic Expression in Tumor Tissue Policy Number: Original Effective Date: MM.12.009 12/02/2008 Line(s) of Business: Current Effective Date Section: 05/25/2018 Other Miscellaneous
Exosomal Del 1 as a potent diagnostic marker for breast cancer : A prospective cohort study
GBCC 2017: ABS-0017 Exosomal Del 1 as a potent diagnostic marker for breast cancer : A prospective cohort study Soo Jung Lee 1, Jeeyeon Lee 2, Jin Hyang Jung 2, Ho Yong Park 2, Chan Hyeong Lee 3, Pyong
Patient Information. Name: (Last) (First) (Middle) Address: (Street) (City) (State) (Zip) Home Phone: Cell Phone: address:
Patient Information Name: (Last) (First) (Middle) Address: (Street) (City) (State) (Zip) Home Phone: Cell Phone: Email address: Birth date: _ Age: Social Security.: When is the best time to contact you?
K. M. Sorensen Utah State University, Logan, Utah
K. M. Sorensen Utah State University, Logan, Utah T. E. Doyle, B. D. Borget, M. Cervantes, J. A. Chappell, B. J. Curtis, M. A. Grover, J. E. Roring, J. E. Stiles, and L. A. Thompson Utah Valley University,
The contribution of the population biobank of ISPO
The contribution of the population biobank of ISPO Domenico Palli Molecular and Nutritional Epidemiology Unit - ISPO, Florence d.palli@ispo.toscana.it 9 March 2012, Rome Challenges and Opportunities of
Evaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients
BIOSCIENCES BIOTECHNOLOGY RESEARCH ASIA, December 2015. Vol. 12(3), 2221-2225 Evaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients S.M. Hosseini¹, H. Shahbaziyan
Biobank Way to Sustainable Research
Biobank Way to Sustainable Research Johanna Arola, MD. PhD Biobanking for Future Research and Health 28-29 May 2018 Academy of Finland Johanna Arola Pathologist (Liver and Endocrine) Research group at
Speaker s Bureau. Travel expenses. Advisory Boards. Stock. Genentech Invuity Medtronic Pacira. Faxitron. Dune TransMed7 Genomic Health.
Management of DCIS Shawna C. Willey, MD, FACS Professor of Surgery, Georgetown University Director, Medstar Regional Breast Health Program Chief, Department of Surgery Medstar Georgetown University Hospital
Breast Cancer Screening
Scan for mobile link. Breast Cancer Screening What is breast cancer screening? Screening examinations are tests performed to find disease before symptoms begin. The goal of screening is to detect disease
Mastectomy For Treatment, For Prevention, For Prophylaxis Not as Simple as Following Data
Mastectomy For Treatment, For Prevention, For Prophylaxis Not as Simple as Following Data Nathalie Johnson, MD FACS Medical Director, Legacy Cancer Institute and Breast Health Centers Objectives Understand
Chief Investigator Adele Francis University of Birmingham UK. Prof MWR Reed (CoI) University of Sheffield
The LORIS Trial: A multicentre, randomised phase III trial of standard surgery versus active monitoring in women with newly diagnosed low risk ductal carcinoma in situ. Chief Investigator Adele Francis
PMT3 study. Prospective Monoamine-producing Tumor study. Phase 3. pheochromocytomas and paragangliomas
PMT3 study Prospective Monoamine-producing Tumor study Phase 3 An international multicenter prospective study of biomarkers for prediction of malignancy and hereditary pheochromocytomas and paragangliomas
Pathology of Lobular & Ductal Preneoplasia. Syed A Hoda, MD Weill-Cornell, New York, NY
Pathology of Lobular & Ductal Preneoplasia Syed A Hoda, MD Weill-Cornell, New York, NY Proliferative Epithelial Changes in Breast A wide range of proliferative epithelial changes occur in the breast There
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C, Heidel RE, Desai P, McLoughlin J, Panella T, Bell
Interval Cancers in BreastScreen Aotearoa
Interval Cancers in BreastScreen Aotearoa 2008 2009 Released 2018 nsu.govt.nz Citation: National Screening Unit. 2018. Interval Cancers in BreastScreen Aotearoa 2008 2009. Wellington: Ministry of Health.
Follow-up in breast cancer patients: intensive vs minimal, centralized vs distributed. Alessandra Huscher
Follow-up in breast cancer patients: intensive vs minimal, centralized vs distributed Alessandra Huscher Follow-up in breast cancer patients: facts and myths What is exactly follow-up? an action or thing
Acute: Symptoms that start and worsen quickly but do not last over a long period of time.
Cancer Glossary Acute: Symptoms that start and worsen quickly but do not last over a long period of time. Adjuvant therapy: Treatment given after the main treatment. It usually refers to chemotherapy,
Radiation Therapy for the Oncologist in Breast Cancer
REVIEW ARTICLE Chonnam National University Medical School Sung-Ja Ahn, M.D. Adjuvant Tamoxifen with or without in Patients 70 Years of Age with Stage I ER-Positive Breast Cancer: Efficacy Outcomes (10
Evaluations & CE Credits
Evaluations & CE Credits Nursing Contact Hours, CME and CHES credits are available. Please visit www.phlive.org to fill out your evaluation and complete the post-test. 1 Breast Density and Breast Cancer
At many centers in the United States and worldwide,
ORIGINAL ARTICLES A Declining Rate of Completion Axillary Dissection in Sentinel Lymph Node-positive Breast Cancer Patients Is Associated With the Use of a Multivariate Nomogram Julia Park, MS, Jane V.